目的对比研究乳腺癌中免疫组化法检测c-erbB2蛋白表达和荧光免疫原位杂交法(FISH)检测HER2基因扩增,并评估其临床价值。方法免疫组化染色法及FISH法分别检测42例乳腺癌组织中c-erbB2蛋白表达及HER2基因扩增状况,并进行对比分析。结果42例乳腺癌中c-erbB2蛋白表达(+++)者22例(52.38%),表达(++)者20例(47.62%);42例乳腺癌中有20例(47.62%)出现HER2基因扩增,22例(52.38%)无扩增。两种方法的检测结果差异无统计学意义(P>0.05);但二者的吻合度一般,(k=0.430,P<0.05)。结论免疫组化可以作为临床治疗是否应用赫赛汀(Herceptin)的初筛,免疫组化呈阳性或强阳性的病例有必要进一步进行HER2基因扩增的检测,来确定临床治疗是否应用Herceptin,指导化疗药物的选择及判断患者的预后。 Objective To compare the expression of c-erbB2 protein in breast cancer with immunohistochemistry and fluorescence in situ hybridization (FISH) to detect the amplification of HER2 gene and evaluate its clinical value. Methods Immunohistochemical staining and FISH were used to detect the expression of c-erbB2 protein and the amplification of HER2 gene in 42 cases of breast cancer, respectively, and compared with each other. Results Twenty-two cases (52.6%) had positive expression of c-erbB2 protein (+++) in 42 cases, while 20 cases (47.62%) expressed (++) in 20 cases HER2 gene amplification, 22 cases (52.38%) without amplification. There was no significant difference between the two methods (P> 0.05). However, there was no significant difference between the two methods (k = 0.430, P <0.05). Conclusion Immunohistochemistry can be used as clinical treatment of Herceptin screening, immunohistochemical positive or strong positive cases of the need for further HER2 gene amplification to determine whether the clinical treatment of Herceptin, guidance Choice of chemotherapy drugs and prognosis of patients.